Dysregulation of autophagy as a common mechanism in lysosomal storage diseases

Essays in Biochemistry

Volumn 61, Issue 6, 2017, Pages 733-749

  Seranova, Elena ^a   Connolly, Kyle J ^a   Zatyka, Malgorzata ^a   Rosenstock, Tatiana R ^b   Barrett, Timothy ^a   Tuxworth, Richard I ^a   Sarkar, Sovan ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Medical School of Santa Casa of Sao Paulo SP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; AUTOPHAGY; GENETICS; HUMAN; LIPIDOSIS; LYSOSOME; LYSOSOME STORAGE DISEASE; METABOLISM; PHYSIOLOGY;

ANIMALS; AUTOPHAGY; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; SPHINGOLIPIDOSES;

EID: 85038813070     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/EBC20170055     Document Type: Review

References (167)

1. Luzio, J.P., Pryor, P.R. and Bright, N.A. (2007) Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622-632
2. Perera, R.M. and Zoncu, R. (2016) The lysosome as a regulatory hub. Annu. Rev. Cell Dev. Biol. 32, 223-253
3. Xu, H. and Ren, D. (2015) Lysosomal physiology. Annu. Rev. Physiol. 77, 57-80
4. Futerman, A.H. and van Meer, G. (2004) The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 554-565
5. Platt, F.M., Boland, B. and van der Spoel, A.C. (2012) The cell biology of disease: lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J. Cell Biol. 199, 723-734
6. Parenti, G., Andria, G. and Ballabio, A. (2015) Lysosomal storage diseases: from pathophysiology to therapy. Annu. Rev. Med. 66, 471-486
7. Boustany, R.M. (2013) Lysosomal storage diseases-The horizon expands. Nat. Rev. Neurol. 9, 583-598
8. Mizushima, N., Levine, B., Cuervo, A.M. and Klionsky, D.J. (2008) Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075
9. Ravikumar, B., Sarkar, S., Davies, J.E., Futter, M., Garcia-Arencibia, M., Green-Thompson, Z.W. et al. (2010) Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90, 1383-1435
10. Levine, B. and Kroemer, G. (2008) Autophagy in the pathogenesis of disease. Cell 132, 27-42
11. Stolz, A., Ernst, A. and Dikic, I. (2014) Cargo recognition and trafficking in selective autophagy. Nat. Cell Biol. 16, 495-501
12. Boya, P., Reggiori, F. and Codogno, P. (2013) Emerging regulation and functions of autophagy. Nat. Cell Biol. 15, 713-720
13. Zhou, J., Tan, S.H., Nicolas, V., Bauvy, C., Yang, N.D., Zhang, J. et al. (2013) Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res. 23, 508-523
14. Lieberman, A.P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S.U. and Ballabio, A. (2012) Autophagy in lysosomal storage disorders. Autophagy 8, 719-730
15. Ward, C., Martinez-Lopez, N., Otten, E.G., Carroll, B., Maetzel, D., Singh, R. et al. (2016) Autophagy, lipophagy and lysosomal lipid storage disorders. Biochim. Biophys. Acta 1861, 269-284
16. Klionsky, D.J. and Schulman, B.A. (2014) Dynamic regulation of macroautophagy by distinctive ubiquitin-like proteins. Nat. Struct. Mol. Biol. 21, 336-345
17. Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D. et al. (1998) A protein conjugation system essential for autophagy. Nature 395, 395-398
18. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T. et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO 19, 5720-5728
19. Mizushima, N. (2007) Autophagy: process and function. Genes Dev. 21, 2861-2873
20. Ganley, I.G. (2013) Autophagosome maturation and lysosomal fusion. Essays Biochem. 55, 65-78
21. Saftig, P. and Klumperman, J. (2009) Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623-635
22. Reggiori, F. and Ungermann, C. (2017) Autophagosome maturation and fusion. J. Mol. Biol. 429, 486-496
23. Levine, B., Liu, R., Dong, X. and Zhong, Q. (2015) Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology. Trends Cell Biol. 25, 533-544
24. Nguyen, T.N., Padman, B.S., Usher, J., Oorschot, V., Ramm, G. and Lazarou, M. (2016) Atg8 family LC3/GABARAP proteins are crucial for autophagosome-lysosome fusion but not autophagosome formation during PINK1/Parkin mitophagy and starvation. J. Cell Biol. 215, 857-874
25. McEwan, D.G., Popovic, D., Gubas, A., Terawaki, S., Suzuki, H., Stadel, D. et al. (2015) PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and LC3/GABARAP proteins. Mol. Cell 57, 39-54
26. Wang, Y., Li, L., Hou, C., Lai, Y., Long, J., Liu, J. et al. (2016) SNARE-mediated membrane fusion in autophagy. Semin. Cell Dev. Biol. 60, 97-104
27. Itakura, E., Kishi-Itakura, C. and Mizushima, N. (2012) The hairpin-Type tail-Anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell 151, 1256-1269
28. Diao, J., Liu, R., Rong, Y., Zhao, M., Zhang, J., Lai, Y. et al. (2015) ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature 520, 563-566
29. Tsuboyama, K., Koyama-Honda, I., Sakamaki, Y., Koike, M., Morishita, H. and Mizushima, N. (2016) The ATG conjugation systems are important for degradation of the inner autophagosomal membrane. Science 354, 1036-1041
30. Settembre, C., Di Malta, C., Polito, V.A., Arencibia, M.G., Vetrini, F., Erdin, S. et al. (2011) TFEB links autophagy to lysosomal biogenesis. Science 332, 1429-1433
31. Settembre, C., Fraldi, A., Medina, D.L. and Ballabio, A. (2013) Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 14, 283-296
32. Medina, D.L., Di Paola, S., Peluso, I., Armani, A., De Stefani, D., Venditti, R. et al. (2015) Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. Cell Biol. 17, 288-299
33. He, C. and Klionsky, D.J. (2009) Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43, 67-93
34. Sarkar, S. (2013) Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: Autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem. Soc. Trans. 41, 1103-1130
35. Sarkar, S., Floto, R.A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M. et al. (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111
36. Williams, A., Sarkar, S., Cuddon, P., Ttofi, E.K., Saiki, S., Siddiqi, F.H. et al. (2008) Novel targets for Huntingtons disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4, 295-305
37. Kim, Y.C. and Guan, K.L. (2015) mTOR: A pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25-32
38. Saxton, R.A. and Sabatini, D.M. (2017) mTOR signaling in growth, metabolism, and disease. Cell 168, 960-976
39. Sarkar, S. (2013) Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntingtons disease and other neurodegenerative disorders. Drug Discover. Today 10, e137-e144
40. Levine, B., Packer, M. and Codogno, P. (2015) Development of autophagy inducers in clinical medicine. J. Clin. Invest. 125, 14-24
41. Rubinsztein, D.C., Codogno, P. and Levine, B. (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discover. 11, 709-730
42. Blommaart, E.F.C., Luiken, J.J.F.P., Blommaart, P.J.E., van Woerkom, G.M. and Meijer, A.J. (1995) Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. 270, 2320-2326
43. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y. et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
44. Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A. and Rubinsztein, D.C. (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein. J. Biol. Chem. 282, 5641-5652
45. Jiang, P. and Mizushima, N. (2014) Autophagy and human diseases. Cell Res. 24, 69-79
46. Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786
47. Nixon, R.A. (2013) The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997
48. Menzies, F.M., Moreau, K. and Rubinsztein, D.C. (2011) Protein misfolding disorders and macroautophagy. Curr. Opin. Cell Biol. 23, 190-197
49. Nita, D.A., Mole, S.E. and Minassian, B.A. (2016) Neuronal ceroid lipofuscinoses. Epileptic Disord. 18, 73-88
50. Palmer, D.N., Barry, L.A., Tyynela, J. and Cooper, J.D. (2013) NCL disease mechanisms. Biochim. Biophys. Acta 1832, 1882-1893
51. Mole, S.E. and Cotman, S.L. (2015) Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim. Biophys. Acta 1852, 2237-2241
52. Simonati, A., Pezzini, F., Moro, F. and Santorelli, F.M. (2014) Neuronal ceroid lipofuscinosis: The increasing spectrum of an old disease. Curr. Mol. Med. 14, 1043-1051
53. Ca?rcel-Trullols, J., Kova?cs, A.D. and Pearce, D.A. (2015) Cell biology of the NCL proteins: What they do and dont do. Biochim. Biophys. Acta. 1852, 2242-2255
54. Brandenstein, L., Schweizer, M., Sedlacik, J., Fiehler, J. and Storch, S. (2016) Lysosomal dysfunction and impaired autophagy in a novel mouse model deficient for the lysosomal membrane protein Cln7. Hum. Mol. Genet. 25, 777-791
55. Thelen, M., Dauue, M., Schweizer, M., Hagel, C., Wong, A.M.S., Cooper, J.D. et al. (2012) Disruption of the autophagy-lysosome pathway is involved in neuropathology of the nclf mouse model of neuronal ceroid lipofuscinosis. PLoS One 7, e35493, https://doi.org/10.1371/journal.pone.0035493
56. Leinonen, H., Keksa-Goldsteine, V., Ragauskas, S., Kohlmann, P., Singh, Y., Savchenko, E. et al. (2017) Retinal degeneration in a mouse model Of CLN5 disease is associated with compromised autophagy. Sci. Rep. 7, 1597
57. Cannelli, N., Garavaglia, B., Simonati, A., Aiello, C., Barzaghi, C., Pezzini, F. et al. (2009) Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochem. Biophys. Res. Commun. 379, 892-897
58. Cao, Y., Espinola, J.A., Fossale, E., Massey, A.C., Cuervo, A.M., MacDonald, M.E. et al. (2006) Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281, 20483-20493
59. Lojewski, X., Staropoli, J.F., Biswas-Legrand, S., Simas, A.M., Haliw, L., Selig, M.K. et al. (2014) Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum. Mol. Genet. 23, 2005-2022
60. Vidal-Donet, J.M., Ca?rcel-Trullols, J., Casanova, B., Aquado, C. and Knecht, E. (2013) Alterations in ROS activity and lysosomal pH account for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts. PLoS One 8, e55526, https://doi.org/10.1371/journal.pone.0055526
61. Chandrachud, U., Walker, M.W., Simas, A.M., Heetveld, S., Petcherski, A., Klein, M. et al. (2015) Unbiased cell-based screening in a neuronal cell model of batten disease highlights an interaction between Ca2+ homeostasis, autophagy, and CLN3 Protein function. J. Biol. Chem. 290, 14361-14380
62. Schultz, M.L., Tecedor, L., Stein, C.S., Stamnes, M.A. and Davidson, B.L. (2014) CLN3 Deficient cells display defects in the ARF1-Cdc42 pathway and actin-dependent events. PLoS One 9, e96647, https://doi.org/10.1371/journal.pone.0096647
63. Shacka, J.J. and Roth, K.A. (2005) Cathepsin deficiency as a model for neuronal ceroid lipofuscinoses. Am. J. Pathol. 167, 1473-1476
64. Koike, M., Nakanishi, H., Saftig, P., Ezaki, J., Isahara, K., Ohsawa, Y. et al. (2000) Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20, 6898-6906
65. Koike, M., Shibata, M., Waguri, S., Yoshimura, K., Tanida, I., Kominami, E. et al. (2005) Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167, 1713-1728
66. Shacka, J.J., Klocke, B.J., Young, C., Shibata, M., Olney, J.W., Uchiyama, Y. et al. (2007) Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J. Neurosci. 27, 2081-2090
67. Olsen, A.S.B. and Fgeman, N.J. (2017) Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 7, https://doi.org/10.1098/rsob.170069
68. Platt, F.M. (2014) Sphingolipid lysosomal storage disorders. Nature 510, 68-75
69. Sandhoff, K. and Kolter, T. (2003) Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. B Biol. Sci. 358, 847-861
70. Schuchman, E.H. and Desnick, R.J. (2017) Types A and B Niemann-Pick disease. Mol. Genet. Metab. 120, 27-33
71. Vanier, M.T. (2010) Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16
72. Storch, J. and Xu, Z. (2009) Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim. Biophys. Acta 1791, 671-678
73. Sarkar, S., Carroll, B., Buganim, Y., Maetzel, D., Ng, A.H.M., Cassady, J.P. et al. (2013) Impaired autophagy in the lipid-storage disorder Niemann-Pick Type C1 disease. Cell Rep. 5, 1302-1315
74. Maetzel, D., Sarkar, S., Wang, H., Abi-Mosleh, L., Xu, P., Cheng, A.W. et al. (2014) Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep. 2, 866-880
75. Boland, B., Smith, D.A., Mooney, D., Jung, S.S., Walsh, D.M. and Platt, F.M. (2010) Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J. Biol. Chem. 285, 37415-37426
76. Liao, G., Yao, Y., Liu, J., Yu, Z., Cheung, S., Xie, A. et al. (2007) Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1-/-mouse brain. Am. J. Pathol. 171, 962-975
77. Pacheco, C.D., Kunkel, R. and Lieberman, A.P. (2007) Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum. Mol. Genet. 16, 1495-1503
78. Meske, V., Erz, J., Priesnitz, T. and Ohm, T.G. (2014) The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability. Neurobiol. Dis. 64, 88-97
79. Ordonez, M.P., Roberts, E.A., Kidwell, C.U., Yuan, S.H., Plaisted, W.C. and Goldstein, L.S. (2012) Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1. Hum. Mol. Genet. 21, 2651-2662
80. Lee, H., Lee, J.K., Park, M.H., Hong, Y.R., Marti, H.H., Kim, H. et al. (2014) Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons. Nat. Commun. 5, 5514
81. Fraldi, A., Annunziata, F., Lombardi, A., Kaiser, H.J., Medina, D.L., Spampanato, C. et al. (2010) Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO 29, 3607-3620
82. Lloyd-Evans, E., Morgan, A.J., He, X., Smith, D.A., Elliot-Smith, E., Sillence, D.J. et al. (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14, 1247-1255
83. Kiselyov, K., Yamaguchi, S., Lyons, C.W. and Muallem, S. (2010) Aberrant Ca2+ handling in lysosomal storage disorders. Cell Calcium 47, 103-111
84. Guo, H., Zhao, M., Qiu, X., Deis, J.A., Huang, H., Tang, Q.Q. et al. (2016) Niemann-Pick type C2 deficiency impairs autophagy-lysosomal activity, mitochondrial function, and TLR signaling in adipocytes. J. Lipid Res. 57, 1644-1658
85. Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M. et al. (2009) Autophagy regulates lipid metabolism. Nature 458, 1131-1135
86. Mistry, P.K., Lopez, G., Schiffmann, R., Barton, N.W., Weinreb, N.J. and Sidransky, E. (2017) Gaucher disease: progress and ongoing challenges. Mol. Genet. Metab. 120, 8-21
87. Hruska, K.S., LaMarca, M.E., Scott, C.R. and Sidransky, E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567-583
88. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K. et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82, 192-207
89. Vaccaro, A.M., Motta, M., Tatti, M., Scarpa, S., Masuelli, L., Bhat, M. et al. (2010) Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum. Mol. Genet. 19, 2987-2997
90. Tamargo, R.J., Velayati, A., Goldin, E. and Sidransky, E. (2012) The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257-263
91. Awad, O., Sarkar, C., Panicker, L.M., Miller, D., Zeng, X., Sgambato, J.A. et al. (2015) Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet. 24, 5775-5788
92. Tatti, M., Motta, M., Di Bartolomeo, S., Scarpa, S., Cianfanelli, V., Cecconi, F. et al. (2012) Reduced cathepsins B and D cause impaired autophagic degradation that can be almost completely restored by overexpression of these two proteases in Sap C-deficient fibroblasts. Hum. Mol. Genet. 21, 5159-5173
93. Sun, Y., Liou, B., Ran, H., Skelton, M.R., Williams, M.T., Vorhees, C.V. et al. (2010) Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum. Mol. Genet. 19, 1088-1097
94. Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A., Brandner, S. et al. (2013) Mitochondria and quality control defects in a mouse model of gaucher disease-links to Parkinsons disease. Cell Metab. 17, 941-953
95. Y-h, Xu, K, Xu, Sun, Y., Liou, B., Quinn, B., R-h, Li et al. (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet. 23, 3943-3957
96. Farfel-Becker, T., Vitner, E.B., Kelly, S.L., Bame, J.R., Duan, J., Shinder, V. et al. (2014) Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 23, 843-854
97. Kinghorn, K.J., Gronke, S., Castillo-Quan, J.I., Woodling, N.S., Li, L., Sirka, E. et al. (2016) A Drosophila model of neuronopathic gaucher disease demonstrates lysosomal-Autophagic defects and altered mTOR Signalling and is functionally rescued by rapamycin. J. Neurosci. 36, 11654-11670
98. Bassi, M.T., Manzoni, M., Monti, E., Pizzo, M.T., Ballabio, A. and Borsani, G. (2000) Cloning of the gene encoding a novel integral membrane protein, mucolipidin-And identification of the two major founder mutations causing mucolipidosis Type IV. Am. J. Hum. Genet. 67, 1110-1120
99. Bargal, R., Avidan, N., Ben-Asher, E., Olender, Z., Zeigler, M., Frumkin, A. et al. (2000) Identification of the gene causing mucolipidosis type IV. Nat. Genet. 26, 118-123
100. LaPlante, J.M., Ye, C.P., Quinn, S.J., Goldin, E., Brown, E.M., Slaugenhaupt, S.A. et al. (2004) Functional links between mucolipin-1 and Ca2+-dependent membrane trafficking in mucolipidosis IV. Biochem. Biophys. Res. Commun. 322, 1384-1391
101. Eichelsdoerfer, J.L., Evans, J.A., Slaugenhaupt, S.A. and Cuajungco, M.P. (2010) Zinc dyshomeostasis is linked with the loss of mucolipidosis IV-Associated TRPML1 ion channel. J. Biol. Chem. 285, 34304-34308
102. Dong, X.-P., Cheng, X., Mills, E., Delling, M., Wang, F., Kurz, T. et al. (2008) The type IV mucolipidosis-Associated protein TRPML1 is an endolysosomal iron release channel. Nature 455, 992-996
103. De Leo, M.G., Staiano, L., Vicinanza, M., Luciani, A., Carissimo, A., Mutarelli, M. et al. (2016) Autophagosome-lysosome fusion triggers a lysosomal response mediated by TLR9 and controlled by OCRL. Nat. Cell Biol. 18, 839-850
104. Micsenyi, M.C., Dobrenis, K., Stephney, G., Pickel, J., Vanier, M.T., Slaugenhaupt, S.A. et al. (2009) Neuropathology of the Mcoln1-/- knockout mouse model of mucolipidosis Type IV. J. Neuropathol. Exp. Neurol. 68, 125-135
105. Venkatachalam, K., Long, A.A., Elsaesser, R., Nikolaeva, D., Broadie, K. and Montell, C. (2008) Motor deficit in a Drosophila model of mucolipidosis Type IV due to defective clearance of apoptotic cells. Cell 135, 838-851
106. Miedel, M.T., Rbaibi, Y., Guerriero, C.J., Colletti, G., Weixel, K.M., Weisz, O.A. et al. (2008) Membrane traffic and turnover in TRP-ML1-deficient cells: A revised model for mucolipidosis type IV pathogenesis. J. Exp. Med. 205, 1477-1490
107. Thompson, E.G., Schaheen, L., Dang, H. and Fares, H. (2007) Lysosomal trafficking functions of mucolipin-1 in murine macrophages. BMC Cell Biol. 8, 54, https://doi.org/10.1186/1471-2121-8-54
108. Curcio-Morelli, C., Charles, F.A., Micsenyi, M.C., Cao, Y., Venugopal, B., Browning, M.F. et al. (2010) Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol. Dis. 40, 370-377
109. Venugopal, B., Mesires, N.T., Kennedy, J.C., Curcio-Morelli, C., LaPlante, J.M., Dice, J.F. et al. (2009) Chaperone-mediated autophagy is defective in mucolipidosis type IV. J. Cell. Physiol. 219, 344-353
110. Oldfors, A. and DiMauro, S. (2013) New insights in the field of muscle glycogenoses. Curr. Opin. Neurol. 26, 544-553
111. Godfrey, R. and Quinlivan, R. (2016) Skeletal muscle disorders of glycogenolysis and glycolysis. Nat. Rev. Neurol. 12, 393-402
112. Nishino, I. (2003) Autophagic vacuolar myopathies. Curr. Neurol. Neurosci. Rep. 3, 64-69
113. Malicdan, M.C. and Nishino, I. (2012) Autophagy in lysosomal myopathies. Brain Pathol. 22, 82-88
114. Raben, N., Plotz, P. and Byrne, B.J. (2002) Acid α-glucosidase deficiency (glycogenosis Type II, Pompe disease). Curr. Mol. Med. 2, 145-166
115. Dasouki, M., Jawdat, O., Almadhoun, O., Pasnoor, M., McVey, A.L., Abuzinadah, A. et al. (2014) Pompe disease: literature review and case series. Neurol. Clin. 32, 751-776, ix
116. Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R.J., Zaal, K., Ralston, E. et al. (2006) Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. 59, 700-708
117. Nascimbeni, A.C., Fanin, M., Masiero, E., Angelini, C. and Sandri, M. (2012) The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 19, 1698-1708
118. Raben, N., Hill, V., Shea, L., Takikita, S., Baum, R., Mizushima, N. et al. (2008) Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum. Mol. Genet. 17, 3897-3908
119. Zirin, J., Nieuwenhuis, J. and Perrimon, N. (2013) Role of autophagy in glycogen breakdown and its relevance to chloroquine myopathy. PLoS Biol. 11, e1001708, https://doi.org/10.1371/journal.pbio.1001708
120. Kotoulas, O.B., Kalamidas, S.A. and Kondomerkos, D.J. (2004) Glycogen autophagy. Microsc. Res. Tech. 64, 10-20
121. Nishino, I., Fu, J., Tanji, K., Yamada, T., Shimojo, S., Koori, T. et al. (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406, 906-910
122. Bandyopadhyay, U., Kaushik, S., Varticovski, L. and Cuervo, A.M. (2008) The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol. Cell. Biol. 28, 5747-5763
123. Tanaka, Y., Guhde, G., Suter, A., Eskelinen, E.-L., Hartmann, D., Lullmann-Rauch, R. et al. (2000) Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902-906
124. Eskelinen, E.-L., Illert, A.L., Tanaka, Y., Schwarzmann, G., Blanz, J., von Figura, K. et al. (2002) Role of LAMP-2 in lysosome biogenesis and autophagy. Mol. Biol. Cell 13, 3355-3368
125. Nascimbeni, A.C., Fanin, M., Angelini, C. and Sandri, M. (2017) Autophagy dysregulation in Danon disease. Cell Death Dis. 8, e2565
126. Hashem, S.I., Murphy, A.N., Divakaruni, A.S., Klos, M.L., Nelson, B.C., Gault, E.C. et al. (2017) Impaired mitophagy facilitates mitochondrial damage in Danon disease. J. Mol. Cell Cardiol. 108, 86-94
127. Dowling, J.J., Moore, S.A., Kalimo, H. and Minassian, B.A. (2015) X-linked myopathy with excessive autophagy: A failure of self-eating. Acta Neuropathol. (Berl.) 129, 383-390
128. Ramachandran, N., Munteanu, I., Wang, P., Ruggieri, A., Rilstone, J.J., Israelian, N. et al. (2013) VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol. (Berl.) 125, 439-457
129. Munteanu, I., Kalimo, H., Saraste, A., Nishino, I. and Minassian, B.A. (2017) Cardiac autophagic vacuolation in severe X-linked myopathy with excessive autophagy. Neuromuscul. Disord. 27, 185-187
130. Mariño, G., Madeo, F. and Kroemer, G. (2011) Autophagy for tissue homeostasis and neuroprotection. Curr. Opin. Cell Biol. 23, 198-206
131. Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I. et al. (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880-884
132. Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R. et al. (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889
133. Singh, R. and Cuervo, A.M. (2012) Lipophagy: connecting autophagy and lipid metabolism. Int. J. Cell Biol. 2012, 282041
134. Youle, R.J. and Narendra, D.P. (2011) Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9-14
135. Green, D.R. and Levine, B. (2014) To be or not to be? how selective autophagy and cell death govern cell fate. Cell 157, 65-75
136. Schneider, J.L. and Cuervo, A.M. (2014) Autophagy and human disease: emerging themes. Curr. Opin. Genet. Dev. 26, 16-23
137. Lee, J., Giordano, S. and Zhang, J. (2012) Autophagy, mitochondria and oxidative stress: cross-Talk and redox signalling. Biochem. J. 441, 523-540
138. Sarkar, S., Ravikumar, B., Floto, R.A. and Rubinsztein, D.C. (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16, 46-56
139. Sarkar, S., Perlstein, E.O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R.L. et al. (2007) Small molecules enhance autophagy and reduce toxicity in Huntingtons disease models. Nat. Chem. Biol. 3, 331-338
140. Madeo, F., Zimmermann, A., Maiuri, M.C. and Kroemer, G. (2015) Essential role for autophagy in life span extension. J. Clin. Invest. 125, 85-93
141. Morselli, E., Galluzzi, L., Kepp, O., Criollo, A., Maiuri, M.C., Tavernarakis, N. et al. (2009) Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging 1, 961-970
142. Kuo, S.Y., Castoreno, A.B., Aldrich, L.N., Lassen, K.G., Goel, G., Danci, V. et al. (2015) Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proc. Natl Acad. Sci. U.S.A. 112, E4281-E4287
143. Sarkar, S., Maetzel, D., Korolchuk, V.I. and Jaenisch, R. (2014) Restarting stalled autophagy a potential therapeutic approach for the lipid storage disorder, Niemann-Pick type C1 disease. Autophagy 10, 1137-1140
144. Palmieri, M., Pal, R., Nelvagal, H.R., Lotfi, P., Stinnett, G.R., Seymour, M.L. et al. (2017) mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat. Commun. 8, 14338
145. DeBosch, B.J., Heitmeier, M.R., Mayer, A.L., Higgins, C.B., Crowley, J.R., Kraft, T.E. et al. (2016) Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. Sci. Signal. 9, ra21
146. Chang, J.-W., Choi, H., Cotman, S.L. and Jung, Y.-K. (2011) Lithium rescues the impaired autophagy process in CbCln3-ex7/8/-ex7/8 cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition. J. Neurochem. 116, 659-668
147. Lim, J.-A., Li, L., Shirihai, O.S., Trudeau, K.M., Puertollano, R. and Raben, N. (2017) Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol. Med. 9, 353-370
148. Canonico, B., Cesarini, E., Salucci, S., Luchetti, F., Falcieri, E., Di Sario, G. et al. (2016) Defective autophagy, mitochondrial clearance and lipophagy in Niemann-Pick Type B lymphocytes. PLoS One 11, e0165780, https://doi.org/10.1371/journal.pone.0165780
149. Pallet, N. and Legendre, C. (2013) Adverse events associated with mTOR inhibitors. Expert Opin. Drug Saf. 12, 177-186
150. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A. et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 325, 473-477
151. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J. and Bjorklund, A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl Acad. Sci. U.S.A. 110, E1817-E1826
152. Martini-Stoica, H., Xu, Y., Ballabio, A. and Zheng, H. (2016) The autophagy-lysosomal pathway in neurodegeneration: A TFEB perspective. Trends Neurosci. 39, 221-234
153. Sardiello, M. (2016) Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases. Ann. N.Y. Acad. Sci. 1371, 3-14
154. Napolitano, G. and Ballabio, A. (2016) TFEB at a glance. J. Cell Sci. 129, 2475-2481
155. Medina Diego, L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C. et al. (2011) Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell 21, 421-430
156. Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J.-A., Annunziata, F. et al. (2013) Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol. Med. 5, 691-706
157. Sato, Y., Kobayashi, H., Higuchi, T., Shimada, Y., Ida, H. and Ohashi, T. (2016) TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle. Mol. Ther.-Methods Clin. Dev. 3, 16054
158. Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., Medina, D. et al. (2008) A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet. 17, 119-129
159. Desnick, R.J. and Schuchman, E.H. (2012) Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307-335
160. Ratko, T.A., Marbella, A., Godfrey, S. and Aronson, N. (2013) Enzyme-Replacement Therapies for Lysosomal Storage Diseases. Agency for Healthcare Research and Quality, Comparative Effectiveness Technical Briefs, Rockville (MD), Report No.: 12(13)-EHC154-EF
161. Cox, T.M. (2010) Recommendations for treating patients with Gaucher disease with emerging enzyme products. Blood Cells Mol. Dis. 44, 84-85
162. Aerts, J.M.F.G., Yasothan, U. and Kirkpatrick, P. (2010) Velaglucerase alfa. Nat. Rev. Drug Discover. 9, 837-838
163. Hollak, C.E. (2012) An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evidence 7, 15-20
164. McEachern, K.A., Fung, J., Komarnitsky, S., Siegel, C.S., Chuang, W.-L., Hutto, E. et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91, 259-267
165. Bennett, L.L. and Mohan, D. (2013) Gaucher disease and its treatment options. Ann. Pharmacother. 47, 1182-1193
166. Ripolone, M., Violano, R., Ronchi, D., Mondello, S., Nascimbeni, A., Colombo, I. et al. (2017) Effects of short-To-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol. Appl. Neurobiol.
167. Ashe, K.M., Taylor, K.M., Chu, Q., Meyers, E., Ellis, A., Jingozyan, V. et al. (2010) Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol. Genet. Metab. 100, 309-315